Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Announces Pandemic Flu as Next Development Program; Gets DoD Funding

NEW YORK, Dec. 14 (GenomeWeb News) - With initial funding from the Department of Defense, Alnylam Pharmaceuticals will advance its pandemic flu project into a development program, the company announced today.


The project will join the pipeline of other RNAi therapeutics. The company expects to submit an investigational new drug application for an RNAi therapeutic for pandemic flu as early as the end of 2006.


The funding came from DoD's Defense Advanced Research Projects Agency, Alnylam said. The amount was not disclosed.


The Alnylam pandemic flu program is focused on the development of an RNAi therapeutic targeting sequences that are highly conserved across all flu genomes, including those of avian origin such as the H5N1 strain.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.